From Early 2020 To Q3: Biogen Shifts Aducanumab Filing Expectations Again

Mobile Electronic Traffic Sign stating “expect Delays” taken at sunset with traffic blurred driving past the sign and traffic cones
Biogen will file its aducanumab BLA in Q3 versus prior guidance of early 2020 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business